Bial

BIAL is an innovative international pharmaceutical company with products available in 55 countries. The company is committed to contributing to the improvement of human health and quality of life for people from all over the world. "Caring for your health" is the group's motto, with strategic focus areas being innovation, internationalization, and quality. BIAL dedicates over 20% of its annual revenue to research and development (R&D), establishing an ambitious R&D program aimed at therapeutic innovation. The group’s key areas of focus are neuroscience and cardiology. BIAL has launched eslicarbazepine acetate, an epilepsy medication, which is already being marketed in the United States and several European countries. BIAL has also developed opicapone, a compound for Parkinson’s disease, which has been commercialized in Europe. The company anticipates launching new drugs in the coming years to strengthen its international presence.